Danoprevir Sodium

达诺瑞韦钠

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameDanoprevir Sodium
Drug Alias Namedanoprevirum达诺瑞韦danoprevir丹诺瑞韦钠丹诺瑞韦 +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsHepatitis C, ChronicHepatitis CVirus Diseases
Global Approved IndicationsHepatitis C
Approved Indications in ChinaHepatitis C
Original Approved Country/TerritoryMainland China
Original Approved Date2018/06/08
Country/TerritoryCzechiaCanadaUnited States +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesArray BiopharmaAscletis Pharma (China) Co LtdF. Hoffmann-La Roche Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJointown Pharmaceutical Group Co LtdAscletis Pharmaceutical (Zhejiang) Co Ltd
Inactive CompaniesAscletis Pharma IncF. Hoffmann-La Roche LtdAscletis Biological Technology (Hangzhou) Co Ltd
Active IndicationsHepatitis C
Inactive IndicationsHepatitis C, ChronicVirus Diseases

Other Information

ATC CodeJ05AP
Related LinksWikipediaDrugBankKEGG